Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Oncolytics Bio (ONC.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 40,327
  • Shares Outstanding, K 26,358
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,037 K
  • 60-Month Beta 1.83
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.69
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.95
  • Most Recent Earnings -0.16 on 09/30/19
  • Next Earnings Date 11/12/19
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.10 +39.09%
on 11/18/19
1.86 -17.74%
on 12/03/19
-0.07 (-4.38%)
since 11/06/19
3-Month
0.48 +218.75%
on 10/02/19
1.92 -20.31%
on 11/04/19
+0.60 (+64.52%)
since 09/06/19
52-Week
0.48 +218.75%
on 10/02/19
3.25 -52.92%
on 01/08/19
-1.47 (-49.00%)
since 12/06/18

Most Recent Stories

More News
Cancer Drugs Poised to Improve as New Developments Help Previous Therapies Target Better

USA News Group - A stunning revelation came back in April, when an Oxford published study pointed to only 3% of the cancer drugs tested between 2000 and 2015 were approved to treat patients, whereas another...

ONCY : 1.14 (unch)
ONC.TO : 1.53 (+3.38%)
SRNE : 3.52 (+7.98%)
AZN : 47.68 (+0.13%)
BNTX : 24.37 (+8.36%)
SNY : 46.03 (-0.11%)
Oncolytics Biotech(R) Announces Exercise of Warrants

Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the exercise of warrants from it's August 2019 financing....

ONCY : 1.14 (unch)
ONC.TO : 1.53 (+3.38%)
Big Pharma Gaining Increased Interest in Fighting Cancer With Oncolytic Virus Therapies

USA News Group - As the global oncology drug market is projected to grow at a rate of 7.6% CAGR to hit $176.5 billion by 2025, there's a growing interest within the big pharma sector to tap into the power...

MRK : 88.85 (+0.11%)
AMGN : 233.77 (+0.15%)
ABBV : 86.98 (+0.30%)
BMY : 59.95 (+0.79%)
ONCY : 1.14 (unch)
ONC.TO : 1.53 (+3.38%)
Oncolytics Biotech(R) Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma

MRK : 88.85 (+0.11%)
ONCY : 1.14 (unch)
ONC.TO : 1.53 (+3.38%)
Oncolytics Biotech(R) to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights

SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 5, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today...

ONCY : 1.14 (unch)
ONC.TO : 1.53 (+3.38%)
Oncolytics Biotech(R) Provides Update on Partner Adlai Nortye's Clinical Progress

Adlai received National Medical Products Administration approval for phase 3 clinical trials in China

ONCY : 1.14 (unch)
ONC.TO : 1.53 (+3.38%)
Breast Cancer Awareness Month Arrives With New Teamwork From Biotech Developers on the Way

USA News Group - As October rolled in to welcome the 35th annual Breast Cancer Awareness Month, hope remains alive as new drugs continue to develop from the biotech sector. These include the smaller cap...

PFE : 38.29 (+0.68%)
MRK : 88.85 (+0.11%)
RHHBY : 38.5700 (+0.36%)
INFI : 1.24 (-0.80%)
ONCY : 1.14 (unch)
ONC.TO : 1.53 (+3.38%)
Oncolytics Biotech(R) and PrECOG Announce Collaboration for BRACELET-1 (PrE0113) Study in Metastatic Breast Cancer

Study seeks to confirm predictive and prognostic biomarkers demonstrating pelareorep can expand application of checkpoint inhibitors in HR+-metastatic breast cancer

ONCY : 1.14 (unch)
ONC.TO : 1.53 (+3.38%)
Oncolytics Biotech(R) Appoints Experienced Financial and Strategic Leader Leonard Kruimer to Board of Directors

SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 17, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, is...

JNJ : 140.38 (+0.59%)
ONCY : 1.14 (unch)
ONC.TO : 1.53 (+3.38%)
ZEAL : 32.87 (+5.83%)
MDCO : 84.21 (+0.37%)
Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors

Across 13 clinical studies and a broad range of cancers, up to 96 percent of tumor samples tested positive for replicating pelareorep virus after intravenous delivery

ONCY : 1.14 (unch)
ONC.TO : 1.53 (+3.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar